Virios Therapeutics, Inc. (NASDAQ:VIRI) Director Acquires $58,911.00 in Stock

Virios Therapeutics, Inc. (NASDAQ:VIRIGet Rating) Director William Pridgen bought 13,450 shares of Virios Therapeutics stock in a transaction dated Tuesday, May 17th. The shares were bought at an average cost of $4.38 per share, for a total transaction of $58,911.00. Following the completion of the acquisition, the director now owns 36,469 shares in the company, valued at approximately $159,734.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

William Pridgen also recently made the following trade(s):

  • On Tuesday, March 29th, William Pridgen bought 600 shares of Virios Therapeutics stock. The shares were bought at an average cost of $4.94 per share, for a total transaction of $2,964.00.
  • On Wednesday, March 23rd, William Pridgen bought 2,197 shares of Virios Therapeutics stock. The shares were bought at an average cost of $5.46 per share, for a total transaction of $11,995.62.

Shares of VIRI traded up $0.11 during trading hours on Wednesday, hitting $4.64. 315 shares of the company were exchanged, compared to its average volume of 17,394. Virios Therapeutics, Inc. has a fifty-two week low of $3.30 and a fifty-two week high of $7.45. The firm’s fifty day moving average is $4.47 and its 200 day moving average is $5.25.

Virios Therapeutics (NASDAQ:VIRIGet Rating) last released its earnings results on Thursday, March 17th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.02). During the same period in the prior year, the business earned ($1.25) earnings per share. On average, research analysts predict that Virios Therapeutics, Inc. will post -2.19 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. Masters Capital Management LLC lifted its position in shares of Virios Therapeutics by 8.3% during the 3rd quarter. Masters Capital Management LLC now owns 650,000 shares of the company’s stock worth $3,439,000 after buying an additional 50,000 shares during the last quarter. Vanguard Group Inc. raised its position in Virios Therapeutics by 63.4% in the first quarter. Vanguard Group Inc. now owns 241,666 shares of the company’s stock valued at $1,082,000 after purchasing an additional 93,800 shares during the last quarter. Cetera Advisors LLC raised its position in Virios Therapeutics by 100.0% in the third quarter. Cetera Advisors LLC now owns 48,432 shares of the company’s stock valued at $256,000 after purchasing an additional 24,216 shares during the last quarter. Captrust Financial Advisors bought a new position in Virios Therapeutics in the third quarter valued at about $212,000. Finally, Millennium Management LLC bought a new position in Virios Therapeutics in the third quarter valued at about $152,000. Institutional investors and hedge funds own 11.40% of the company’s stock.

About Virios Therapeutics (Get Rating)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Recommended Stories

Insider Buying and Selling by Quarter for Virios Therapeutics (NASDAQ:VIRI)

Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.